A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia

Conditions

• Severe Hypertriglyceridemia

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Solbinsiran — DRUG
  Administered SC
• Placebo — DRUG
  Administered SC

Study Details

The purpose of this study is to evaluate the safety and efficacy of solbinsiran in lowering triglycerides and other lipid measures compared to placebo in participants with severe hypertriglyceridemia. Participants will receive two subcutaneous injections.

Key Dates

Start date

Dec 8, 2025

Status verified

Apr 2026

Primary completion

Mar 31, 2027

Completion

Aug 31, 2027

Study Design

Enrollment

60 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: Solbinsiran
  Participants will receive solbinsiran subcutaneously (SC)
• Placebo Comparator: Placebo
  Participants will receive placebo SC

Primary Outcome Measure

Change from Baseline in Triglycerides [ Time Frame: Baseline, Weeks 16-24 (Time-Average) ]

Central Contacts

• Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
  317-615-4559
  [email protected]
• Physicians interested in becoming principal investigators please contact
  [email protected]

Locations (29)

Find similar trials in Phoenix, AZ

Related Studies

• Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis
  PHASE3 · Recruiting · Arrowhead Pharmaceuticals · Los Angeles, California
• A Study to Assess the Safety, Tolerability and Efficacy of ION775
  PHASE2 · Recruiting · Ionis Pharmaceuticals, Inc. · Lincoln, California